Orasure technologies director Kenny John P. buys $151,217 in stock

Published 28/02/2025, 03:18
Orasure technologies director Kenny John P. buys $151,217 in stock

Kenny John P., a director at Orasure Technologies Inc. (NASDAQ:OSUR), recently acquired a significant number of shares in the company. According to a Form 4 filing with the Securities and Exchange Commission, John purchased 47,659 shares of Orasure common stock on February 27, 2025. The shares were bought at a weighted average price of $3.1729 each, amounting to a total investment of approximately $151,217. This insider purchase comes as the stock trades near its 52-week low of $2.69, with InvestingPro analysis indicating the company is currently undervalued.

The transaction was executed in multiple trades, with prices ranging from $3.08 to $3.21 per share. Following this purchase, John now directly owns 70,915 shares in the company. Orasure Technologies, based in Bethlehem, Pennsylvania, specializes in the production of surgical and medical instruments and apparatus. The company maintains a strong financial position with a current ratio of 9.95 and more cash than debt on its balance sheet. According to InvestingPro data, analysts expect the company to return to profitability this year, with 10+ additional insights available for subscribers.

In other recent news, OraSure Technologies reported fourth-quarter 2024 earnings, revealing a revenue of $37.4 million, which exceeded analyst expectations by approximately $730,000. The company’s core revenue grew by 10% year-over-year, driven by strong sales in HIV, HCV, and syphilis testing, though its gross margin of 40.1% fell short of the anticipated 43.4%. Despite the revenue beat, Citi adjusted its price target for OraSure from $9 to $6, maintaining a Buy rating on the stock, indicating ongoing investor concerns about future profitability and market uncertainties. OraSure’s management provided guidance for the first quarter of 2025, projecting revenues between $27.5 million and $31.5 million, with the core business expected to generate $27 to $31 million. The company has also been focusing on strategic acquisitions and product innovations, including the acquisition of Sherlock Biosciences, expected to bolster its molecular diagnostics platform. Additionally, OraSure ended the quarter with a strong cash position of $268 million and aims to expand its gross margin to 50% through operational efficiencies. However, uncertainties in U.S. funding and international markets continue to pose challenges, impacting the company’s revenue outlook for the upcoming quarter.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.